Meritz Fire & Marine Insurance Obtains Exclusive Rights for Diagnosis Benefits of Central Nervous System and Articular Cartilage Diseases

Meritz Fire & Marine Insurance announced on the 8th that it has obtained a 3-month exclusive usage right for two special riders: 'Specific Two Major Central Nervous System Disease Diagnosis Benefit' and 'Bone and Joint Cartilage Benign Tumor Diagnosis Benefit.'

[Asia Economy Reporter Oh Hyung-gil] Meritz Fire & Marine Insurance announced on the 8th that it has obtained a 3-month exclusive usage right for two special riders: 'Diagnosis Benefit for Two Specific Major Central Nervous System Diseases' and 'Diagnosis Benefit for Benign Bone and Joint Cartilage Tumors.'

The Diagnosis Benefit for Two Specific Major Central Nervous System Diseases covers conditions such as brain meningitis, encephalitis, and abscesses or inflammatory diseases occurring in intracranial veins. The Diagnosis Benefit for Benign Bone and Joint Cartilage Tumors covers benign tumors (benign neoplasms) occurring in bones, joints, or cartilage of the arms, legs, pelvis, spine, knees, and shoulders.

Reflecting the recent increase in patients treated with non-surgical methods due to advances in medical technology, these riders allow coverage based solely on disease code diagnosis, regardless of treatment type such as medication, procedures, or surgery. Additionally, according to statistics from the Health and Medical Big Data Open System, the diseases covered by these two riders occur across all age groups from children to adults, meeting the coverage needs of the entire population.

Both riders are available for subscription in the 'Meritz Dumppokdamun Diagnosis Coverage Insurance' launched in July.

A Meritz Fire & Marine Insurance official stated, "We will continue to develop new products to provide services that meet customer demands," adding, "We aim to enhance product competitiveness by launching products that cover diseases in coverage blind spots."